Terconazole

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

槟榔碱是一种毒蕈碱乙酰胆碱受体激动剂。

Arecoline is a muscarinic acetylcholine receptor agonist. Arecoline induces ADP ribosylation of histones and chromatid relaxation in spleen and bone marrow cells.(In Vitro):Terconazole inhibits the growth of Candida albicans ATCC 44859 in a concentration-related manner, but with modest effects noted at levels from 0.1 to 10 μM when the yeast is grown on media favoring the cell form. The inhibitory potency of terconazole on yeast cell viability varies with the strain and species of Candida tested. The susceptibility of C. albicans ATCC 44859 to terconazole is markedly enhanced when the yeast is grown on Eagle minimum essential medium, which favors mycelium formation. There is a progression of changes, from loss of mycelia formation at 0.1 μM terconazole through complete necrosis at 100 μM. Terconazole blocks the morphogenetic transformation from the yeast into the filamentous form at concentrations of 0.008 to 0.05 microgram/mL.(In Vivo):A 3-day once-daily intravaginal application of terconazole 0.8% is usually sufficient to provide a functional therapeutic period of 7 days because of prolonged high biologically active antifungal levels in the vagina. No side effects are observed at any concentration of terconazole.

Terconazole inhibits the growth of Candida albicans ATCC 44859 in a concentration-related manner, but with modest effects noted at levels from 0.1 to 10 μM when the yeast is grown on media favoring the cell form. The inhibitory potency of terconazole on yeast cell viability varies with the strain and species of Candida tested. The susceptibility of C. albicans ATCC 44859 to terconazole is markedly enhanced when the yeast is grown on Eagle minimum essential medium, which favors mycelium formation. There is a progression of changes, from loss of mycelia formation at 0.1 μM terconazole through complete necrosis at 100 μM. Terconazole blocks the morphogenetic transformation from the yeast into the filamentous form at concentrations of 0.008 to 0.05 microgram/mL.

A 3-day once-daily intravaginal application of terconazole 0.8% is usually sufficient to provide a functional therapeutic period of 7 days because of prolonged high biologically active antifungal levels in the vagina. No side effects are observed at any concentration of terconazole.

NSC 331942 | R-42470 | (±)-Terconazole

Microbiology/Virology

Antifection

14-α Demethylase

Infection

——

67915-31-5

532.46

C26H31Cl2N5O3

>98% (HPLC)

Soluble in DMSO

CC(N1CCN(C2=CC=C(OC[C@H]3O[C@](CN4N=CN=C4)(C5=CC=C(Cl)C=C5Cl)OC3)C=C2)CC1)C

1-(4-(((2S,4R)-2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-isopropylpiperazine

(-20℃)

With Ice Pack

≥ 2 years